Pegylated interferon alfa-ccr5 antagonist combination hiv therapy
CA 2365900 A1 · Owner: Laughlin, Mark A. · Inventors: Laughlin, Mark A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The use of a pegylated interferon-alfa and a CCR5 antagonist further in , association with at least one of ribavirin IL-2, IL-12, pentafuside alone or , in combination with an anti-HIV-1 drug therapy e.g. HAART, for preparation , of a medicament for the treatment of HIV-1 infections as well as HIV-1 infections as well as HIV-1 and HCV co-infections in treatment-naive as well as treatment-experienced adult and pediatric patients are disclosed.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 1, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 1, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 1, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.